Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



1 Key Question Remains after MannKind's Giant Leap

Biotech MannKind (Nasdaq: MNKD) is one of the health care sector's top performers, approaching a double in 2014 and has notched two year gains over 250%. But what is next for investors in the industry darling?

After FDA approval for its flagship inhaled insulin product Afrezza, it appears the bulls have completely vanquished the MannKind bears -- or are the bears merely licking their substantial wounds, waiting to make another swipe at shares? Because while it may seem like smooth sailing for the biotech now that it has a unique product and an effective monopoly in a huge indication, there is one key question remaining: how will it sell?

In this episode of Where the Money Is, health care analysts David Williamson and Michael Douglass  discuss what MannKind investors should expect next, the kind of patients MannKind should target, and which big pharma makes the most sense as a partner or potential acquirer. Watch and find out.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Read/Post Comments (5) | Recommend This Article (16)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 06, 2014, at 9:07 PM, Jim1865 wrote:

    Who would listen to Michael Douglass about MNKD? This pudgy kid predicted that Afrezza would not be approved and said that the AdCom was the second AdCom for Afrezza. It wasn't. Afrezza only had one AdCom. If this idiot can't get even that right does anyone really think he has researched this stock and knows anything about it?

    I feel sorry for anyone that listened to this idiot and shorted MNKD but then, just by looking at him you should've have able to tell he was not a valid source of information. Of course Motley Fool is not a valid source.

  • Report this Comment On July 07, 2014, at 6:42 AM, bufnyfan1 wrote:

    I now understand why they call this site "Motley Fool" because this character Douglass is a FOOL--so a pharmaceutical company will give MNKD a lousy deal to market Afrezza because MNKD can't go on without a deal--baloney--tell me pal how much will the "technosphere" technology alone be worth to a big drug maker? that alone is worth a separate deal on its own-MNKD is going to be able to get a deal on their OWN terms--they don't have to be "desperate" as this "fool" would seem to imply--and I agree why would I believe the opinion of someone who said Afrezza wouldn't get through ADCOM little alone get final FDA approval???

  • Report this Comment On July 07, 2014, at 10:24 AM, larryw101 wrote:

    These two clowns are so amateurish that is laughable.They call this a show? Maybe a comedy show.

    All they do is laugh when the one or the other speaks, and foremost, neither of them knows anything about MNKD. They are actually comical to watch.

    Motley Fool = Garbage Journalism.

  • Report this Comment On July 08, 2014, at 11:08 AM, missjessiecat wrote:

    antimatter0007 • 13 hours ago Flag

    Afrezza tremendous potential w bigger pie for diabetic treatment.........

    For those who don't fully understand diabetes, I hope this little explanation will convince you how important Afrezza is to the diabetic community. The very reason why diabetics suffer kidney failures, heart failures, ischemic limbs, and blindness is poorly controlled blood glucose level. This applies to all diabetic population, whether they are still producing insulin or not at all. For those producing little or none will be insulin dependent, requiring injection and AFrezza. And those still producing insulin will still require Afrezza for post meals; they may not need baseline long acting insulin because their pancrease is still producing adequate for baseline but inadequate during meal glucose surges. Years of these poorly controlled glucose surges that the body suffers damages of kideney failure, heart failure, loss of limbs and eyeslight.

    Thus, Afrezza 's ability to control glucose surges within minutes, peak effect in 12-15 minutes, works like native pancreas. ALL diabetics (both insulin and noninsulin dependent) will use Afrezza to control their post meal glucose surges; this works well in developed countries where we like to splurge. How is this compared to the current gold standard SQ insulin? SQ insulin takes about an hour for peak effect, in the mean time the body suffers post meal glucose surges.

    With FDA approval the worse is behind us! So don't lose sight of the tramendous potential. Insulin market share is projected to be around $30 bil for 2016. Afrezza is gonna steal some of that pie but the convenience and rapid onset of action will create its own use, or adjunct to diabetic treatment for tighter glucose control. EVERY DIABETIC IS GOING TO WANT TO USE AFREZZA to prevent heart failure, kidney failure, loss of limbs and eyesight.

  • Report this Comment On July 09, 2014, at 10:01 AM, 5kitkat wrote:

    Does MNKD want a partner or buyout? Yes, because that would make it very easy to market. Does MNKD need a partner to market and succeed? Absolutely not, if you did any research at all, you would see that Al Mann's previous companies all marketed products for years before partnering or buyout- that's EVERY previous Al Mann company- Spectrolab, Heliotek, Pacesetter Systems, Inc., Minimed & Advanced Bionics.

    You can badmouth Al Mann all you want, but it will only will serve to discredit you. As for all you shorts- get ready to soil them!

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3018849, ~/Articles/ArticleHandler.aspx, 8/28/2015 9:28:47 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

David Williamson

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...

Today's Market

updated 12 hours ago Sponsored by:
DOW 16,654.77 369.26 0.00%
S&P 500 1,987.66 47.15 0.00%
NASD 4,812.71 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/27/2015 4:01 PM
LLY $83.74 Up +2.64 +0.00%
Eli Lilly & Co. CAPS Rating: ****
MNKD $3.91 Down +0.00 +0.00%
MannKind Corp CAPS Rating: **
AZN $31.61 Up +0.48 +0.00%
AstraZeneca plc (A… CAPS Rating: ****
NVO $56.16 Up +0.79 +0.00%
Novo Nordisk CAPS Rating: *****